

- 11:00 72. Comparison of Topical Capsaicin and Parenteral Acyclovir in the Treatment of Primary Genital Herpes: Effect of Treatment on the Subsequent Development of Recurrent Disease. L.R. Stanberry, N. Bourne, and F.J. Bravo. *Children's Hospital Research Foundation, Cincinnati, OH, USA.*
- 11:15 73. The Single-Dose Pharmacokinetics and Metabolism of 882C87, a Potent Anti-VZV Agent with a Long Half-Life. R.W. Peck, R. Wootton, B.C. Weatherley, and J. Posner. *Wellcome Research Laboratories, Beckenham, Kent, UK.*
- 11:30 74. Increased Bioavailability of Acyclovir from Oral Valaciclovir in Healthy Volunteers. M.R. Blum, J. Soul-Lawton, C.M. Smith, N.T. On, J. Posner, and P.E. Rolan. *Burroughs Wellcome Co., Research Triangle Park, NC, USA; and Wellcome Research Laboratories, Beckenham, Kent, UK.*
- 11:45 75. n-Docosanol Cream is an Effective Topical Treatment of Recurrent Herpes Labialis. D.H. Katz, L. Habbema, K. De Boule, and G.A. Roders. *Lidak Pharmaceuticals, La Jolla, CA, USA; Academisch Ziekenhuis Rotterdam Dijkzigt, Rotterdam; Aalst, Belgium; and Brocades Pharma BV, Leiderdorp, The Netherlands.*
- 12:00 Lunch

Oral Session IV: Respiratory and Hepatitis Virus Infections

Chairpersons: R.W. Sidwell and J.L. Gerin

- 1:30pm 76. The Development of an Antirhinovirus Model Based on Small Molecule Conformations. G.D. Diana, D.J. Aldous, A.M. Tresurywala, E.P. Jaeger, and D.C. Pevear. *Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA, USA.*
- 2:00 77. The Anti-Influenza Virus Activity of a Novel Neuraminidase (Sialidase) Inhibitor 4-Guanidino Neu5Ac2en. D.M. Ryan, J. Ticehurst, and M.H. Dempsey. *Glaxo Group Research Ltd, Greenford, Middlesex, UK.*
- 2:15 78. In Vitro Anti-myxovirus Activity of Polyoxometalates. S. Shigeta, S. Mori, M. Hosoya, M. Baba, R.F. Schinazi, A.M. Khenkin, and C.L. Hill. *Fukushima Medical College, Fukushima, Japan; and Emory University School of Medicine, Atlanta, GA, USA.*
- 2:30 79. A Variant of Echovirus 12 that Requires the Selective Antiviral Inhibitor Rhodanine for Replication. H.J. Eggers and J.P. Kruppenbacher. *Universitaet zu Koeln, Koeln, Germany.*

- 2:45 80. Inhibition of Hepatitis B Virus Replication In Vitro by Antisense Oligonucleotides. B. Korba, F. Wells, K. Jones, R. Engle, A. Buckler-White, and J. Gerin. *Georgetown University Medical Center, Rockville, MD, USA.*
- 3:00 81. The Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar, N-Butyl-Deoxynojirimycin. T.M. Block, X. Lu, F.M. Platt, G.R. Foster, W.H. Gerlich, B.S. Blumberg, and R.A. Dwek. *Jefferson Medical College, Philadelphia, PA; University of Oxford, Justus Liebig Universität, Giessen, Germany; and St. Mary's Hospital, London, UK.*
- 3:15 82. Antiviral Activity of Penciclovir, A Novel Antiherpesvirus Compound, Against Duck Hepatitis B Virus In Vitro. S.A. Locarnini, T. Shaw, P. Amor, and M.R. Boyd. *Fairfield Hospital, and Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia; and SmithKline Beecham Pharmaceuticals, Surrey, UK.*
- 3:30 83. Inhibition of Duck Hepatitis B Virus DNA Polymerase by the Triphosphate of Fialuridine. A.J. Schilke, K.A. Staschke, and J.M. Colacino. *Lilly Research Laboratories, Indianapolis, IN, USA.*
- 3:45 84. Effects of IFN γ on HBV Gene Expression in Transgenic Mice. H. Ueda, G. Jay, and J.D. Gangemi. *Jerome H. Holland Laboratory, Rockville, MD; and Clemson University-Greenville Hospital System, Clemson, SC, USA.*
- 4:00 85. Development of (-)- β -D-2,6-Diaminopurine Dioxolane as a Potential Antiviral Agent. R.F. Schinazi, H.M. McClure, F.D. Boudinot, Y. Jxiang, and C.K. Chu. *VA Medical Center, Emory University, Decatur, GA; Yerkes Regional Primate Research Center, Emory University, Atlanta, GA, and University of Georgia, Athens, GA, USA.*
- 4:15 86. A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetic Profile, and Preliminary Antiviral Effects of OST-577 (a Human Anti-Hepatitis B Surface Antigen Monoclonal Antibody) Administered to Patients who are Persistently Hepatitis B Antigen Seropositive. D.P. Paar, B.M. Montgomerie, P. Nadler, E.R. Schiff, and R.B. Pollard. *The University of Texas Medical Branch at Galveston, Galveston, TX; Protein Design Labs, Mountain View, CA; and The University of Miami, Miami, FL, USA*

Poster Session II: Herpesvirus Infections

4:30-6:30pm

87. Syntheses and In Vivo Antiviral Activity of Prodrugs of an N7-Isomeric Acyclic Nucleoside Analogue. G. Jähne, G. Gross, M. Helsenberg, T.H. Scholl, and I. Winkler. *Hoechst AG, Frankfurt am Main, Germany.*